Global Diabetic Neuropathy Market Research Report 2023

Growth in global diabetic neuropathy market is highly attributed to consistently increasing diabetic population across the globe linked with growing awareness among people is considered as major market driver for diabetic neuropathy market. Moreover, global market is primarily driven by changing lifestyle which has mostly resulted into unhealthy dietary habits and patterns. In addition, factors such as increasing aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes, and rise in R & D activities in drug discovery and development have contributed in the global growth. However, growth of this market is predominantly restrained by longer approval time for drugs and side effects and rising cost of diabetic neuropathy treatment. Also, stringent regulatory requirement and significant failure rate during the clinical trials expected to be the growth barriers in the years to come.

Highlights

The global Diabetic Neuropathy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Diabetic Neuropathy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Diabetic Neuropathy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Diabetic Neuropathy in Online Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Diabetic Neuropathy include Pfizer, Janssen Pharmaceuticals, Eli Lilly and Company, ACTAVIS, Cephalon, MEDA Pharma & Co. KG, GlaxoSmithKline, NeuroMetrix and Johnson & Johnson Services, Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Diabetic Neuropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Neuropathy.

The Diabetic Neuropathy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Diabetic Neuropathy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Diabetic Neuropathy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.


By Company


Pfizer

Janssen Pharmaceuticals

Eli Lilly and Company

ACTAVIS

Cephalon

MEDA Pharma & Co. KG

GlaxoSmithKline

NeuroMetrix

Johnson & Johnson Services, Inc.

Novartis AG

DAIICHI SANKYO


Segment by Type


Oral

Subcutaneous

Intravenous


Segment by Application


Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diabetic Neuropathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.